

RECEIVED.
SECRETARY OF THE SENATE

03 AUG 15 PM 2:29

| | |
|---|--|
| Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 | Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 |
|---|--|

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

| | | | |
|--|-----------------------------|--|-----------------------------|
| 1. Registrant Name Winstead Sechrest & Minick P.C. | | | |
| 2. Address <input type="checkbox"/> Check if different than previously reported 1450 G Street NW Suite 810 Washington, DC 20005 | | | |
| 3. Principal Place of Business (if different from line 2) City: _____ State/zip (or Country) _____ | | | |
| 4. Contact Name William LaForge | Telephone (202) 572-8000 | E-mail (optional) wlaforge@winstead.com | 5. Senate ID # 42741-595 |
| 7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals | | | 6. House ID # 33542021 |

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇔ Termination Date _____11. No Lobbying **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

| 12. Lobbying Firms | 13. Organizations |
|--|--|
| INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input checked="" type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇔ \$ _____ <div style="text-align: center;">Income (nearest \$20,000)</div> | EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇔ \$ _____ <div style="text-align: center;">Expenses (nearest \$20,000)</div> |
| Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definition. <input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code |

Signature _____ Date 0/14/03

Printed Name and Title _____ William LaForge, Shareholder

LD-2 (REV. 4/03)

PAGE 1 of _

Registrant Name Winstead Sechrest & Minick P.C. Client Name Aventis Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmaceutical.


17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| William LaForge | |
| Frederick D. McClure | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/03

Printed Name and Title William LaFolge, Shareholder / _____